Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Restoring the pharmaceutical industry's reputation

Nature Biotechnology volume 32, pages 983–990 (2014)Cite this article

Subjects

Big pharma's storehouse of trouble has fostered consumer mistrust and a negative view of the industry. How does the industry go about restoring its flagging reputation?

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Main areas in which pharmaceutical marketing departments spent funds in 2012.

References

  1. Harris Interactive. The Harris Poll 2013 RQ. Summary Report. (Harris Interactive, Rochester, NY, February 2013) https://www.harrisinteractive.com/vault/2013%20RQ%20Summary%20Report%20FINAL.pdf

  2. Brigham, A.F. & Linssen, S. Your brand reputational value is irreplaceable. Protect it! Forbes http://www.forbes.com/2010/02/01/brand-reputation-value-leadership-managing-ethisphere.html (February 1, 2010).

    Google Scholar 

  3. Gaines-Ross, L. Corporate Reputation. 12 Steps to Safeguarding and Recovering Reputation. (John Wiley & Sons, Hoboken, NJ, 2008).

    Google Scholar 

  4. Harrison, K. Why a good corporate reputation is important to your organization. Cutting Edge PR http://www.cuttingedgepr.com/articles/corprep_important.asp (April 5, 2014).

    Google Scholar 

  5. Baum, S. Survey finds lack of transparency drags down pharma reputation among patient groups. Medcity News http://medcitynews.com/2013/01/lack-of-transparency-drags-down-pharma-reputation-among-patient-groups-survey/ (15 January 2013).

    Google Scholar 

  6. The Reputation Institute. Corporate Reputation: The Main Driver of Business Value. http://www.reputationinstitute.com/frames/press/CRO%20White%20Paper_%20RI%20UK.pdf (May 2012).

  7. The Pew Charitable Trusts. Persuading the prescribers: pharmaceutical industry marketing and its influence on physicians and patients. http://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2013/11/11/persuading-the-prescribers-pharmaceutical-industry-marketing-and-its-influence-on-physicians-and-patients (11 November 2013).

  8. Bach, P.E., Saltz, L. & Wittes, R.E. In cancer care, cost matters. The New York Times (14 October 2012).

    Google Scholar 

  9. Denning, S. The best of Peter Drucker. Forbes http://www.forbes.com/sites/stevedenning/2014/07/29/the-best-of-peter-drucker/2/ (29 July 2014).

    Google Scholar 

  10. Ward, A. Witty comes out fighting for GSK. Financial Times p15 (28 July 2014).

    Google Scholar 

  11. Porter, E. Motivating corporations to do good. The New York Times http://www.nytimes.com/2014/07/16/business/the-do-good-corporation.html?_r=0 (15 July 2014).

    Google Scholar 

  12. Surowiecki, J. Companies with benefits. The New Yorker (4 August 2014). http://www.newyorker.com/magazine/2014/08/04/companies-benefits

  13. Drews, J. Drug Discov. Today 8, 411–420 (2003).

    Article  Google Scholar 

  14. Grogan, K. Pharma optimistic about future, worried about reputation. PharmaTimes online http://www.pharmatimes.com/mobile/14-06-13/pharma_optimistic_about_future_worried_about_reputation.aspx?r=1 (13 June 2014).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mark Kessel is chairman of the Foundation for Innovative New Diagnostics (FIND), counsel to Shearman and Sterling LLP and a founding partner of Symphony Capital LLP, New York, New York, USA.,

    Mark Kessel

Authors
  1. Mark Kessel
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Mark Kessel.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kessel, M. Restoring the pharmaceutical industry's reputation. Nat Biotechnol 32, 983–990 (2014). https://doi.org/10.1038/nbt.3036

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt.3036

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research